Evidence map›Paper›PMID 36639698›Full record

ArticleDiagnostic pathology2023

Differential diagnosis of uterine adenosarcoma: identification of JAZF1-BCORL1 rearrangement by comprehensive cancer genomic profiling.

Chie Hasegawa, Kota Washimi, Yukihiko Hiroshima, Rika Kasajima, Keiji Kikuchi, Tsuguto Notomi, Hisamori Kato, Toru Hiruma, Shinya Sato, Yoichiro Okubo and 4 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Diagnostic pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Chie HasegawaDepartment of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan.
Kota WashimiDepartment of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan. washimik@kcch.jp.
Yukihiko HiroshimaDivision of Advanced Cancer Therapeutics, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.
Rika KasajimaCenter for Cancer Genome Medicine, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Keiji KikuchiDivision of Advanced Cancer Therapeutics, Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa, Japan.
Tsuguto NotomiDepartment of Gynecology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Hisamori KatoDepartment of Gynecology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Toru HirumaDepartment of Musculoskeletal Tumor Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Shinya SatoDepartment of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan.
Yoichiro OkuboDepartment of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan.
Emi YoshiokaDepartment of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan.
Kyoko OnoDepartment of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan.
Yohei MiyagiCenter for Cancer Genome Medicine, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Tomoyuki YokoseDepartment of Pathology, Kanagawa Cancer Center, 2-3-2 Nakao Asahi-ku, Yokohama, Kanagawa, 241-8515, Japan.
Kanagawa Prefectural Hospital Organization · JP

Funding

Japan Society for the Promotion of Science,Japan JP 16H06277Japan Society for the Promotion of Science,Japan JP 20K16210
6 · The paper itself

Abstract

backgroundUterine adenosarcoma is a rare malignant tumor that accounts for 8% of all uterine sarcomas, and less than 0.2% of all uterine malignancies. However, it is frequently misdiagnosed in clinical examinations, including pathological diagnosis, and imaging studies owing to its rare and non-specific nature, which is further compounded by the lack of specific diagnostic markers. CASE PRESENTATION: We report a case of uterine adenosarcoma for which a comprehensive genomic profiling (CGP) test provided a chance to reach the proper diagnosis. The patient, a woman in her 60s with a history of uterine leiomyoma was diagnosed with an intra-abdominal mass post presentation with abdominal distention and loss of appetite. She was suspected to have gastrointestinal stromal tumor (GIST); the laparotomically excised mass was found to comprise uniform spindle-shaped cells that grew in bundles with a herringbone architecture, and occasional myxomatous stroma. Immunostaining revealed no specific findings, and the tumor was diagnosed as a spindle cell tumor/suspicious adult fibrosarcoma. The tumor relapsed during postoperative follow-up, and showed size reduction with chemotherapy, prior to regrowth. CGP was performed to identify a possible treatment, which resulted in detection of a JAZF1-BCORL1 rearrangement. Since the rearrangement has been reported in uterine sarcomas, we reevaluated specimens of the preceding uterine leiomyoma, which revealed the presence of adenosarcoma components in the corpus uteri. Furthermore, both the uterine adenosarcoma and intra-abdominal mass were partially positive for CD10 and BCOR staining.

conclusionThese results led to the conclusive identification of the abdominal tumor as a metastasis of the uterine adenosarcoma. The JAZF1-BCORL1 rearrangement is predominantly associated with uterine stromal sarcomas; thus far, ours is the second report of the same in an adenosarcoma. Adenosarcomas are rare and difficult to diagnose, especially in atypical cases with scarce glandular epithelial components. Identification of rearrangements involving BCOR or BCORL1, will encourage BCOR staining analysis, thereby potentially resulting in better diagnostic outcomes. Given that platinum-based chemotherapy was proposed as the treatment choice for this patient post diagnosis with adenosarcoma, CGP also indirectly contributed to the designing of the best-suited treatment protocol.

Indexed as

AdenosarcomaLeiomyomaUterine NeoplasmsAgedCo-Repressor ProteinsDiagnosis, DifferentialDNA-Binding ProteinsFemaleGenomicsHumansRepressor ProteinsBCORL1 protein, humanCo-Repressor ProteinsDNA-Binding ProteinsJAZF1 protein, humanRepressor ProteinsComprehensive genomic profilingJAZF1-BCORL1Uterine adenosarcoma

Identifiers

PMID36639698
PMCPMC9837955
OpenAlexW4316039726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.